Dosage adjustment of quinolone antibiotics and angiotensin-converting enzyme inhibitors in patients with renal dysfunction

H. Ohtani, Y. Kinoshita, Y. Nagasaki, H. Sata, A. Miki, M. Tsujimoto, Y. Sawada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to verify an approach for calculating pharmacokinetic parameters suitable for adjusting dosage regimens in patients with renal dysfunction. We carried out a retrospective analysis of the pharmacokinetic profiles of 12 new quinolone antibiotics and 11 angiotensin-converting enzyme inhibitors (ACEIs) in patients with normal and impaired renal function to obtain the renal excretion ratio (Rrenal) of each drug. We demonstrated that the pharmacokinetics of each drug in a patient with renal dysfunction can be adequately estimated using the Rrenal value of each drug together with the creatinine clearance as an index of the individual's renal function. Using the Rrenal value obtained, we could successfully simulate pharmacokinetic profiles of the drugs in publications other than that used to obtain the Rrenal values. On the other hand, age-related changes in the pharmacokinetics of new quinolone antibiotics are not always adequately predicted using the Rrenal value compared to using creatinine clearance alone as an index, and the reasons for this are not fully understood. These results demonstrate that dosage regimens of quinolone antibiotics and ACEIs in patients with renal dysfunction can be adequately optimized using the Rrenal value for each drug using the present approach.

Original languageEnglish
Pages (from-to)428-437
Number of pages10
JournalInternational journal of clinical pharmacology and therapeutics
Volume44
Issue number9
DOIs
Publication statusPublished - 2006 Sep
Externally publishedYes

Keywords

  • Creatinine clearance
  • Elderly
  • Pharmacokinetics
  • Renal failure

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Dosage adjustment of quinolone antibiotics and angiotensin-converting enzyme inhibitors in patients with renal dysfunction'. Together they form a unique fingerprint.

  • Cite this